CHICAGO, Nov. 8 Advanced Life Sciences Holdings,Inc. (Nasdaq: ADLS), today announced that it will host a conference call andlive webcast at 9:00 a.m. Eastern Time on Thursday, November 15, 2007 todiscuss the Company's third quarter financial results. Michael T. Flavin,Ph.D., Chairman & Chief Executive Officer, and other members of the managementteam will also present an update on the Company. A press release reportingthe third quarter financial results will be issued after the U.S. stockmarkets close on Wednesday, November 14, 2007.
The conference call will be webcast simultaneously over the Internet.Please visit the Investor Relations section of Advanced Life Sciences'corporate website www.advancedlifesciences.com. Alternatively, callers mayparticipate in the conference call by dialing 866-510-0704 (domestic) or 617-597-5362 (international). The passcode for the conference call is 57071751.A telephone replay of the call will also be available for 48 hours. Callersmay access the telephone replay by dialing (domestic) 888-286-8010 or 617-801-6888 (international), passcode 51192916.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in thediscovery, development and commercialization of novel drugs in the therapeuticareas of infection, cancer and respiratory diseases. The Company's leadcandidate, cethromycin, is a novel once-a-day antibiotic in late-stageclinical development for the treatment of respiratory tract infectionsincluding CAP. For more information, please visit us on the web atwww.advancedlifesciences.com.
Any statements contained in this press release that relate to futureplans, events or performance are forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties thatcould cause actual results to differ materially from those described in theforward-looking statements. These risks and uncertainties include, amongothers, those relating to technology and product development, clinical trials,market acceptance, government regulation and regulatory approval processes,intellectual property rights and litigation, dependence on collaborativerelationships, ability to obtain financing, competitive products, industrytrends and other risks identified in Advanced Life Sciences' filings with theSecurities and Exchange Commission. Advanced Life Sciences undertakes noobligation to update or alter these forward-looking statements as a result ofnew information, future events or otherwise.
Company Contact: Joe Camp 630-754-4352
Media Contact: Melanie Nimrodi, Financial Relations Board, 312-546-3508
Investors Contact: Kathy Price, Financial Relations Board, 213-486-6547
SOURCE Advanced Life Sciences Holdings, Inc.